Citations

Clear

16280 citation(s) found for "Yu, David".

Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States
Rocca, Walter A. , Petersen, Ronald C. , Hebert, Liesi E., Evans, Denis A. , Hall, Kathleen, Gao, Sujuan , Unverzagt, Frederick W. , Langa, Kenneth M. , Larson, Eric B. , White, Lon R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 20, 2011 | Volume: 7 | Issue: 1 | Pages: 80-93

10.1016/j.jalz.2010.11.002 | PMID 21255746 Get It

Declines in heart disease and stroke mortality rates are conventionally attributed to reductions in cigarette smoking, recognition and treatment of hypertension and diabetes, effective medications to improve serum lipid levels and to reduce clot formation, and general lifestyle improvements. Recent evidence implicates these and other cerebrovascular factors in the development of a substantial proportion of dementia cases. Analyses were undertaken to determine whether corresponding declines in age‐specific prevalence and incidence rates for dementia and cognitive impairment have occurred in recent years. Data spanning 1 or 2 decades were examined from community‐based epidemiological studies in Minnesota, Illinois, and Indiana, and from the Health and Retirement Study, which is a national survey. Although some decline was observed in the Minnesota cohort, no statistically significant trends were apparent in the community studies. A significant reduction in cognitive impairment measured by neuropsychological testing was identified in the national survey. Cautious optimism appears justified.
Passive case‐finding for Alzheimer's disease and dementia in two U.S. communities
Petersen, Ronald C. , Rocca, Walter A. , Larson, Eric B. , Knopman, David S. , Ganguli, Mary

Mayo Clinic

Alzheimer's & Dementia | January 20, 2011 | Volume: 7 | Issue: 1 | Pages: 53-60

10.1016/j.jalz.2010.11.001 | PMID 21255743 Get It

Passive surveillance for disease is a public health approach that relies on documentation available within existing health records for the region or community being studied. Its two primary advantages over active case‐finding are the lower cost of research and the lower burden on the population under study. The effectiveness of passive case‐finding depends on the comprehensiveness of the healthcare coverage in a given community and the adequacy of the available medical records. The Rochester Epidemiology Project has permitted dementia case detection for Olmsted County, Minnesota, using a medical records‐linkage system. These data were compared with case ascertainment using direct assessment of individuals in an epidemiological study of the same community. At the Group Health Research Institute, investigators compared dementia and Alzheimer's disease cases detected using an electronic medical record database search with those identified by a parallel active case‐finding study. In this article, the advantages and disadvantages of passive case‐finding were discussed, and the following conclusion was drawn: the purpose of the study being conducted should determine the case‐finding approach that is to be used.
Safety of Percutaneous Left Atrial Appendage Closure
Reddy, Vivek Y. , Holmes, David R. , Doshi, Shephal K. , Neužil, Petr , Kar, Saibal , Reddy, Vivek Y

Mayo Clinic

Circulation | January 18, 2011 | Volume: 123 | Issue: 4 | Pages: 417-424

10.1161/circulationaha.110.976449 | PMID 21242484 Get It

Background— The Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) randomized trial compared left atrial appendage closure against warfarin in atrial fibrillation (AF) patients with CHADS 2 ≥1. Although the study met the primary efficacy end point of being noninferior to warfarin therapy for the prevention of stroke/systemic embolism/cardiovascular death, there was a significantly higher risk of complications, predominantly pericardial effusion and procedural stroke related to air embolism. Here, we report the influence of experience on the safety of percutaneous left atrial appendage closure. Methods and Results— The study cohort for this analysis included patients in the PROTECT AF trial who underwent attempted device left atrial appendage closure (n=542 patients) and those from a subsequent nonrandomized registry of patients undergoing Watchman implantation (Continued Access Protocol [CAP] Registry; n=460 patients). The safety end point included bleeding- and procedure-related events (pericardial effusion, stroke, device embolization). There was a significant decline in the rate of procedure- or device-related safety events within 7 days of the procedure across the 2 studies, with 7.7% and 3.7% of patients, respectively, experiencing events ( P =0.007), and between the first and second halves of PROTECT AF and CAP, with 10.0%, 5.5%, and 3.7% of patients, respectively, experiencing events ( P =0.006). The rate of serious pericardial effusion within 7 days of implantation, which had made up >50% of the safety events in PROTECT AF, was lower in the CAP Registry (5.0% versus 2.2%, respectively; P =0.019). There was a similar experience-related improvement in procedure-related stroke (0.9% versus 0%, respectively; P =0.039). Finally, the functional impact of these safety events, as defined by significant disability or death, was statistically superior in the Watchman group compared with the warfarin group in PROTECT AF. This remained true whether significance was defined as a change in the modified Rankin score of ≥1, ≥2, or ≥3 (1.8 versus 4.3 events per 100 patient-years; relative risk, 0.43; 95% confidence interval, 0.24 to 0.82; 1.5 versus 3.7 events per 100 patient-years; relative risk, 0.41; 95% confidence interval, 0.22 to 0.82; and 1.4 versus 3.3 events per 100 patient-years; relative risk, 0.43; 95% confidence interval, 0.22 to 0.88, respectively). Conclusion— As with all interventional procedures, there is a significant improvement in the safety of Watchman left atrial appendage closure with increased operator experience. Clinical Trial Registration— URL: http://clinicaltrials.gov . Unique identifier: NCT00129545.
Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure
Maisel, William H., Friedman, Paul A. , Kallinen, Linda M., Mugglin, Andrew S. , Kumar, Kapil , Hodge, David O. , Morrison, Thomas B., Hayes, David L. , Hauser, Robert G.

Mayo Clinic

Circulation | January 18, 2011 | Volume: 123 | Issue: 4 | Pages: 358-363

10.1161/circulationaha.110.975219 | PMID 21242478 Get It

Background— Sprint Fidelis (Fidelis) implantable cardioverter-defibrillator leads are prone to fractures that have caused adverse events, primarily inappropriate shocks, and a few reported deaths. More than 100 000 patients have Fidelis leads. No independent multicenter long-term performance information exists for this lead, and single-center studies suggest that certain patients are at increased risk for Fidelis failure. Our aim was to assess the longevity of Fidelis leads and to evaluate clinical variables and adverse events associated with Fidelis failure. The results were compared with like data for Quattro Secure (Quattro) implantable cardioverter-defibrillator leads implanted at our centers. Methods and Results— This 3-center study included adults ≥18 years of age who received Fidelis or Quattro leads for the prevention of sudden cardiac death. From November 2001 to January 2009,1023 Fidelis and 1668 Quattro leads were implanted and followed up. The failure rate for Fidelis leads was 2.81%/y compared with 0.43%/y for Quattro leads ( P <0.0001). No deaths or injuries occurred as a result of lead failure, but 42% of fractures caused inappropriate shocks. The survival of Fidelis leads at 4 years was 87.0% (95% confidence interval, 83.6 to 90.1) compared with 98.7% (95% confidence interval, 97.9 to 99.4) for Quattro leads ( P <0.0001). Multivariate predictors of Fidelis failure were younger age (hazard ratio, 0.98; 95% confidence interval, 0.96 to 0.99), female gender (hazard ratio, 0.61; 95% confidence interval, 0.40 to 1.00), and cardiac disease ( P =0.041). Conclusions— Compared with Quattro leads, the survival of Fidelis leads continues to decline, and Fidelis failure is notably higher in younger patients, women, individuals with hypertrophic cardiomyopathy, and patients with arrhythmogenic right ventricular dysplasia or channelopathies. These findings have significant implications for the management of patients who have Fidelis leads, and they demonstrate the importance of weighing clinical variables in assessments of implantable cardioverter-defibrillator lead performance.
Tapping into the biology of Alzheimer disease
Knopman, David S.

Mayo Clinic

Neurology | January 13, 2011 | Volume: 76 | Issue: 6 | Pages: 496-497

10.1212/wnl.0b013e31820af995 | PMID 21228299 Get It

Reporting potential bias
Baskin, Patricia K. , Pieper, Kathleen M. , Quimby, Susan, Gross, Robert A. , Knopman, David S.

Mayo Clinic

Neurology | January 10, 2011 | Volume: 76 | Issue: 2 | Pages: 110-112

10.1212/wnl.0b013e318206f646 | PMID 21220716 Get It

Living Donor Liver Transplantation
Gali, Bhargavi , Rosen, Charles B. , Plevak, David J.

Mayo Clinic

Journal of Intensive Care Medicine | January 10, 2011 | Volume: 27 | Issue: 2 | Pages: 71-78

10.1177/0885066610394313 | PMID 21220274 Get It

A perception that living donor liver transplantation can be accomplished with an acceptable donor complication rate and recipient survival rate has led to the acceptance of living donor liver transplantation as a viable alternative to decreased deceased donor transplantation. Careful candidate evaluation and selection has been crucial to the success of this procedure. Advancements in the understanding of the lobar nature of the liver and of liver regeneration have advanced the surgical technique. Initial attempts at adult-to-adult donation utilized the left hepatic lobe, but now have evolved into use of the right hepatic lobe. Size matching is very important to successful graft function in the recipient. There is great concern regarding morbidity and mortality in donors. Biliary complications and infections continue to be among the most highly reported complications, although rates vary among centers and countries. Reports of single center complications have ranged from 9% to 67%. A survey of centers in the United States in 2003 reported complications of 10%. A series from our institution reported complications arising in 13 (33%) of 39 patients. A review focused on documenting donor deaths found 33 living liver donor deaths worldwide. The much publicized immediate postoperative mishap of 2002 that resulted in a donor’s death resulted in a drop in the utilization of living donor liver transplantation in the United States, from which this procedure has never fully recovered. The future development and expansion of living donor liver transplantation depends on open communication regarding donor complications and deaths. Close immediate postoperative monitoring and meticulous management will remain an essential aspect in limiting donor complications and deaths.
Abstract CN13-03: Next-generation stool DNA testing
Ahlquist, David A.

Mayo Clinic

Cancer Prevention Research | January 10, 2011 | Volume: 3 | Issue: 12_Supplement | Pages: CN13-03-CN13-03

10.1158/1940-6207.prev-10-cn13-03 Get It

Abstract Prevention of colorectal cancer (CRC) by screening hinges on the effective detection of precancers. As no conventional screening method fully prevents cancer across the colorectum, there is justification and incentive to consider alternative and complementary approaches. Precancers as Targets for Screening. In addition to curable stage CRC, precancers at greatest risk of progression are the critical screening targets. Adenomas likely account for 70-80% of CRC. While roughly 50% of Americans will acquire adenomas in their lifetime, only 6% develop CRC; so most adenomas do not progress. Advanced adenomas (those ≥1cm or containing high-grade dysplasia or prominent villous histology) appear to confer the highest risk and are generally considered to be the relevant subset for screening. Serrated polyps (sessile serrated adenomas, serrated adenomas, large hyperplastic polyps) are increasingly recognized as important precursors to CRC, especially on the right side. They account for 20-30% of CRCs, are often flat and endoscopically inconspicuous, harbor mutated BRAF and multiple hypermethylated genes, may have a more aggressive natural history, and have routinely been excluded or ignored as outcomes in screening studies1, 2. Flat dysplasia, as occurs sporadically and with inflammatory bowel disease, can be especially difficult to detect endoscopically and may often go undetected until CRC develops. Finally, field changes (molecular alterations occurring prior to phenotypic transformation) represent a largely unexplored target for screening. Limitations of Conventional Screening Tools. The commonly used screening tools have proven to be insensitive for colorectal precancers, especially right-sided ones. Such proximal lesions are above the reach of sigmoidoscopy, which has no effect on incidence of proximal CRC3. Fecal blood tests miss most precancers irrespective of their location4,,5 and have little of no effect on CRC prevention6. Because hemoglobin degrades during colon transit, commonly-used fecal blood tests, such as guaiac cards or FIT, are proportionately less sensitive for right-sided CRC5, 7. And, based on surprising recent reports8,, 9 even colonoscopy as historically practiced may fail to reduce incidence and mortality of right-sided CRC; and this may, in part, be explained by missed serrated polyps. Stool DNA Testing. As extensively reviewed,10 stool assay of exfoliated molecular markers from stool represents a noninvasive, biologically rational, and feasible strategy that continues to evolve technologically. Based on multicenter studies with early sDNA test approaches7,, 11 the American Cancer Society and other organizations endorsed sDNA testing for CRC screening12. Next-generation stool DNA (sDNA) test methods incorporate sample stabilization, the requisite analytical sensitivity to detect pre-cancers at high rates, and broad marker coverage. In a recent tissue study, panels of just 3-4 methylated DNA markers provide complete discrimination between normal colon and CRC or adenomas13. Various sDNA test approaches using new technologies in selected patients have detected 81-100% of CRC. Application of next generation sDNA testing for detection of three critical types of CRC precursors will be the major focus of this brief update. Adenomas. Based on recent reviews10,, 14 various nonoptimized stool DNA tests detect 44-86% of advanced adenomas at specificities of 85-96%. In a comparison on archival stools from a multicenter study,15 analytically sensitive next-generation methods detected significantly more advanced adenomas detection than did early sDNA tests. In a preliminary report using a multimarker next-generation assay,16 we observed that the detection rate increases with size and degree of dysplasia: 62% if ≥1cm, 78% if ≥2cm, and 90% if ≥3cm (comparable to CRC detection); and &gt;80% of adenomas with high-grade dysplasia were detected. In contrast to fecal blood tests which are less sensitive for proximal than distal neoplasms, lesion site does not affect stool DNA test results7. Thus, regardless of anatomic site, adenomas with highest risk of progression appear to be the ones most likely to be detected by sDNA testing. Serrated Polyps. In a preliminary report,17 our group recently showed that advanced serrated polyps (i.e., those ≥1cm) can be detected noninvasively by sDNA testing. Using archived stools from a multicenter screening study, assay of mutated BRAF, methylated vimentin, or the combination detected 50%, 57%, and 71% of sessile serrated adenomas ≥1cm compared to just 7% by prospectively performed Hemoccult or HemoccultSensa (p&lt;0.01) at comparable specificities. Large prospective studies are clearly needed to corroborate and extend these early findings. IBD-related Dysplasia. Conventional colonoscopy surveillance in patients with inflammatory bowel disease (IBD) has limited sensitivity for both premalignant dysplasia and CRC. In a preliminary report,18 our group presented findings from an ongoing multicenter study evaluating sDNA testing for detection of IBD-related neoplasia. We found that stool assay of methylated EYA4 detected 5/5 (100%) of CRCs and 4/5 (80%) of dysplasia at a 90% specificity (using colonoscopy or resected surgical specimens as criterion standards). Thus, sDNA testing appears to be feasible for the noninvasive detection of neoplasia in setting of IBD and could have an important complementary role in surveillance. Further evaluation of sDNA testing for noninvasive screening of IBD-related neoplasia are warranted Optimization and clinical validation of multimarker next-generation sDNA tests for detection of CRC, advanced adenomas, and serrated polyps in the screen setting are currently underway. References: 1. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009;4:343-64. 2. Lu FI et al. Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. Am J Surg Pathol;34:927-34. 3. Atkin WS et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet;375:1624-33. 4. Ahlquist DA et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. Jama 1993;269:1262-7. 5. Morikawa T et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8. 6. Heresbach D et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006;18:427-33. 7. Ahlquist DA et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50, W81. 8. Baxter NN et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8. 9. Brenner H et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst;102:89-95. 10. Ahlquist DA. Molecular detection of colorectal neoplasia. Gastroenterology 2010;138:2127-39. 11. Imperiale TF et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14. 12. Levin B et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008. 13. Zou H et al. Sensitive quantification of methylated markers with a novel methylation specific technology. 2010. 14. Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology 2009;136:2068-73. 15. Zou H et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459-70. 16. Zou H JX et al. Quantitative stool DNA testing for detection of both colorectal cancer and advanced adenoma. Presented at DDW 2009. 17. Hussain FT et al. Noninvasive Detection of Serrated Colorectal Polyps by Stool Assay of Methylated Vimentin and Mutant BRAF Genes. Presented at DDW 2010. 18. Kisiel JB et al. Noninvasive Detection of Colorectal Neoplasia in Inflammatory Bowel Disease by Stool DNA Testing: A Pilot Study. Presented at DDW 2010. Citation Information: Cancer Prev Res 2010;3(12 Suppl):CN13-03.
Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention
Mahoney, Michelle R., Ziegler, Katie L. Allen, Sontag, Stephen J. , Benya, Richard V., Lawson, Michael J. , Weinberg, David S. , Chiorean, Michael , Heigh, Russell I., Levine, Joel B., Della’Zanna, Gary , Rodriguez, Luz M. , Gostout, Christopher J., Mandrekar, Sumithra J. , Smyrk, Thomas C. , Limburg, Paul J. , Schoen, Robert E. , Stoffel, Elena M. , RODRIGUEZ, LUZ MARIA , Richmond, Ellen S.

Mayo Clinic

Cancer Prevention Research | January 6, 2011 | Volume: 4 | Issue: 2 | Pages: 259-269

10.1158/1940-6207.capr-10-0215 | PMID 21209397 Get It

Abstract Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. However, clinical trial data are currently limited. We conducted a randomized, phase II chemoprevention trial involving subjects 40 years or older, with previously resected colon cancer or multiple/advanced colorectal adenomas. Magnification chromoendoscopy (MCE) was performed to identify and characterize rectal aberrant crypt foci (ACF); eligibility criteria required five or more rectal ACFs at baseline. Intervention assignments were as follows: (a) atorvastatin 20 mg qd; (b) sulindac 150 mg bid; (c) oligofructose-enriched inulin (as ORAFTI®Synergy1) 6 gm bid; or (d) control (maltodextrin) 6 gm bid, for 6 months. Percent change in rectal ACF number (%ΔACF) within arm was the primary endpoint. Secondary endpoints included changes in proliferation (Ki67) and apoptosis (caspase-3), as measured from normal mucosa biopsy samples. Among 85 eligible randomized subjects, 76 (86%) completed the trial per protocol. The median (range) of rectal ACF was 9 (5–34) and 8 (0–37) at baseline and postintervention, respectively. The median (SD) for %ΔACF was 5.6 (−69% to 143%), −18.6 (−83% to 160%), −3.6 (−88% to 83%), and −10.0 (−100% to 117%) in the atorvastatin, sulindac, ORAFTI®Synergy1 and control arms, respectively. Neither within-arm (P = 0.12–0.59) nor between-arm (P = 0.30–0.92) comparisons of %ΔACF were statistically significant. The active and control interventions also seemed to have similar effects on mucosal proliferation and apoptosis (P &gt; 0.05 for each comparison). Data from this multicenter, phase II trial do not provide convincing evidence of CRC risk reduction from 6-month interventions with atorvastatin, sulindac, or ORAFTI®Synergy1, although statistical power was limited by the relatively small sample size. Cancer Prev Res; 4(2); 259–69. ©2011 AACR.
Cardiac Safety of Lapatinib Given Concurrently with Paclitaxel and Trastuzumab as Part of Adjuvant Therapy for Patients with HER2+ Breast Cancer: Pilot Data from the Mayo Clinic Cancer Research Consortium Trial RC0639.
Palmieri, Frances M., Johnson, David B. , Colón‐Otero, Gerardo , Diekmann, Brent, Dakhil, Shaker R. , Reinholz, Monica M., McCullough, Ann E. , Rodeheffer, R.J., Perez, Edith A. , Dueck, Amylou C. , Franco, Sandra

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 24_Supplement | Pages: 3086-3086

10.1158/0008-5472.sabcs-09-3086 Get It

Abstract Background: Despite the impressive results of the trastuzumab adjuvant therapy trials, 15% of patients (pts) with HER2 overexpressing or amplified breast cancer developed tumor relapse at 4 years. Lapatinib is a reversible tyrosine kinase inhibitor against ErbB1 and ErbB2. The current study was developed to assess the cardiac safety and feasibility of adding lapatinib to paclitaxel and trastuzumab following doxorubicin and cyclophosphamide as part of adjuvant therapy.Methods: A single-arm phase II study of doxorubicin (A, 60 mg/m2 day 1) and cyclophosphamide (C, 600 mg/m2 day 1) [q2w or q3w for 4 cycles]; followed by PTL: paclitaxel (P, 80 mg/m2 weekly), trastuzumab (T, 4 mg/kg loading dose then 2 mg/kg weekly), and lapatinib (L, 1000 mg PO daily which was later amended to 750 mg) [total of 12 weeks of treatment]; followed by T (6 mg/kg day 1, every 3 weeks) and L (1000 mg PO daily) [total of 40 weeks of treatment] was conducted. The primary endpoint was severe symptomatic congestive heart failure (CHF: New York Heart Association Class III or IV with a drop in left ventricular ejection fraction [LVEF] of at least 10 percentage points to below 50% confirmed by cardiologist) with secondary endpoints of cardiac death and grade 3+ cardiac adverse events (AEs).Results: From April 2007 to October 2008, 109 evaluable pts were enrolled and initiated study treatment. Median age was 51 (range 28-72). Median follow-up is 10.2 months. No pts experienced CHF or cardiac death while on active treatment. One pt had CHF and 1 pt died due to myocardial infarction (MI) after they went off study treatment. The pt with CHF refused further treatment after completing 2 cycles of PTL and had CHF 1.8 months post PTL discontinuation with LVEF of 45% and dyspnea on exertion. The pt with MI went off study treatment due to non-cardiac AEs after completing 2 cycles of PTL and died 2.9 months post PTL discontinuation. Mean LVEF at baseline was 63.6% (N=109, SD=5.7); end of AC was 63.3% (N=104, SD=6.4); end of PTL was 59.9% (N=89, SD=8.3); and cycle 12 was 59.7% (N=66, SD=7.1). Grade 3+ non-hematologic AEs with incidence &gt;5% include diarrhea (N=42, 39% & included both 1000mg & later amended 750mg dosing), fatigue (N=15, 14%), nausea (N=7, 6%), vomiting (N=7, 6%), acne (N=6, 6%), and hypokalemia (N=6, 6%). Pre-treatment cardiac marker data (troponin-T, troponin-I, brain natriuretic peptide, creatine kinase MB isoenzyme) will also be presented.Conclusions: Preliminary data suggest that the inclusion of L does not add to the cardiac profile of T. Data from ALTTO and long-term follow data are needed to confirm the cardiac safety of this regimen. Cardiac marker data are being analyzed in the context of changes in LVEF. We gratefully acknowledge support from the Breast Cancer Research Foundation and GlaxoSmthKline for this study. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3086.